Lack of diversity in clinical trials and genomic databases doesn't just create health disparities — it creates blind spots that limit the commercial reach of precision medicine. The case for inclusion as both an ethical imperative and a market-expansion strategy.

Why the beachhead strategy — winning a narrow application first before expanding — is the right model for life science tools and diagnostics companies trying to disrupt entrenched incumbents.

A practitioner's take on how to make the consulting case interview process more thoughtful, equitable, and effective — improving both candidate experience and the quality of hiring decisions.

Digital biomarkers — measuring health signals through devices and software rather than blood draws — represent the real promise that Theranos obscured. The case for a category that is maturing quietly and building on more solid scientific ground.

Why diagnostic technologies — not just therapeutics — will define the precision medicine era. The infrastructure that makes precision care possible is systematically undervalued.